Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NVX-CoV2373 · TAK-019

Vaccine (Peptide vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by NOVAVAX

Phase 3 Most advanced trial (none active)

NVAX Developer

4 Registered trials

What is NVX-CoV2373?

NVX-CoV2373 is a recombinant nanoparticle-based vaccine containing SARS-CoV-2 spike protein antigen with Matrix-M adjuvant. It induces cell-mediated and antibody-mediated immune responses against SARS-CoV-2, providing active immunization and protection against SARS-CoV-2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TAK-019, SARS-CoV-2 rS/Matrix-M Adjuvant
Drug type: Vaccine (Peptide vaccine)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: immune_activation
Therapy area: Infectious disease
Developer: NOVAVAX (NVAX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: UK9AK2IN1P

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05925127	Phase 2/3	COVID-19	Completed	NVAX
NCT05463068	Phase 3	COVID-19	Completed	NVAX
NCT05372588	Phase 3	COVID-19	Completed	NVAX
NCT04368988	Phase 1/2	COVID-19	Completed	NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19SARS CoV 2 Infection

More from NOVAVAX

CIC Vaccine Phase 3 EBOV GP Vaccine Phase 1 Fluzone HD Phase 2/3 ICC Vaccine Phase 1/2 NanoFlu Phase 3 NVX-CoV2372 Phase 2 NVX-CoV2515 Phase 3 NVX-CoV2540 Phase 3 NVX-CoV2601 Phase 2/3 NVX-CoV2705 Phase 3 qNIV Vaccine Phase 2 SARS-CoV-2 rS Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind NVX-CoV2373

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z